× Industry Reports Services Press Release Contact us About us

Asia Pacific Monoclonal Antibodies Market Forecast 2027 By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use (Hospitals, Clinics), Research Report, Country Outlook (Japan, China, India, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: July 2021 | Publisher: Graphical Research Report ID: GR1894 | Delivery : PDF  Request Free Sample

Report Content

Chapter 1   Methodology

1.1    Market definitions

1.2    Forecast assumptions

1.3    Data sources

1.3.1    Secondary

1.3.1.1    Paid sources

1.3.1.2    Unpaid sources

1.3.2    Primary

Chapter 2   Market Summary

2.1    Asia Pacific monoclonal antibodies industry summary, 2016 – 2027

2.1.1    Country trends

2.1.2    Type trends

2.1.3    Application trends

2.1.4    End-use trends

Chapter 3   Market Analysis

3.1    Industry segmentation

3.2    Industry outlook, 2016 – 2027 (USD Million)

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1    Increasing prevalence of chronic and infectious diseases

3.3.1.2    Growing research and development activities

3.3.1.3    Booming biologics market

3.3.1.4    Rising applications of monoclonal antibodies

3.3.2    Industry pitfalls & challenges

3.3.2.1    High cost of some monoclonal antibody therapeutics

3.3.2.2    Stringent regulatory framework

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter’s analysis

3.6    Competitive review, 2020

3.7    PEST analysis

Chapter 4   Asia Pacific Monoclonal Antibodies Market, By Type

4.1    Market trends

4.2    Fully human

4.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.3    Humanized

4.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.4    Chimeric

4.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

4.5    Others

4.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 5   Asia Pacific Monoclonal Antibodies Market, By Application

5.1    Market trends

5.2    Oncology

5.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.3    Autoimmune diseases

5.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.4    Infectious diseases

5.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

5.5    Others

5.5.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 6   Asia Pacific Monoclonal Antibodies Market, By End-use

6.1    Market trends

6.2    Hospitals

6.2.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

6.3    Clinics

6.3.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

6.4    Others

6.4.1    Market estimates and forecast, by country, 2016 – 2027 (USD Million)

Chapter 7   Asia Pacific Monoclonal Antibodies Market, By Country

7.1    Market trends

7.2    Japan

7.2.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.2.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.2.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

7.3    China

7.3.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.3.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.3.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

7.4    India

7.4.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.4.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.4.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

7.5    Australia

7.5.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.5.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.5.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

7.6    South Korea

7.6.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.6.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.6.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

7.7    Singapore

7.7.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.7.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.7.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

7.8    Indonesia

7.8.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.8.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.8.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

7.9    Thailand

7.9.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.9.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.9.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

7.10    Malaysia

7.10.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.10.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.10.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

7.11    Philippines

7.11.1    Market estimates and forecast, by type, 2016 – 2027 (USD Million)

7.11.2    Market estimates and forecast, by application, 2016 – 2027 (USD Million)

7.11.3    Market estimates and forecast, by end-use, 2016 – 2027 (USD Million)

Chapter 8   Company Profiles

8.1    F. Hoffmann-La Roche Ltd.

8.1.1    Business overview

8.1.2    Financial data

8.1.3    Product landscape

8.1.4    Strategic outlook

8.1.5    SWOT analysis

8.2    AbbVie Inc.

8.2.1    Business overview

8.2.2    Financial data

8.2.3    Product landscape

8.2.4    Strategic outlook

8.2.5    SWOT analysis

8.3    Amgen

8.3.1    Business overview

8.3.2    Financial data

8.3.3    Product landscape

8.3.4    Strategic outlook

8.3.5    SWOT analysis

8.4    Bristol Myers Squibb

8.4.1    Business overview

8.4.2    Financial data

8.4.3    Product landscape

8.4.4    Strategic outlook

8.4.5    SWOT analysis

8.5    Johnson & Johnson

8.5.1    Business overview

8.5.2    Financial data

8.5.3    Product landscape

8.5.4    Strategic outlook

8.5.5    SWOT analysis

8.6    Merck & Co., Inc.

8.6.1    Business overview

8.6.2    Financial data

8.6.3    Product landscape

8.6.4    Strategic outlook

8.6.5    SWOT analysis

8.7    Novartis AG

8.7.1    Business overview

8.7.2    Financial data

8.7.3    Product landscape

8.7.4    Strategic outlook

8.7.5    SWOT analysis

8.8    AstraZeneca

8.8.1    Business overview

8.8.2    Financial data

8.8.3    Product landscape

8.8.4    Strategic outlook

8.8.5    SWOT analysis

8.9    Eli Lilly and Company

8.9.1    Business overview

8.9.2    Financial data

8.9.3    Product landscape

8.9.4    Strategic outlook

8.9.5    SWOT analysis

8.10    GlaxoSmithKline plc

8.10.1    Business overview

8.10.2    Financial data

8.10.3    Product landscape

8.10.4    Strategic outlook

8.10.5    SWOT analysis

8.11    Takeda Pharmaceuticals

8.11.1    Business overview

8.11.2    Financial data

8.11.3    Product landscape

8.11.4    Strategic outlook

8.11.5    SWOT analysis


Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]